{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:43:05Z","timestamp":1747168985573,"version":"3.40.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.pcd.2024.01.006","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T13:40:07Z","timestamp":1706017207000},"page":"210-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["A prospective, multicentre, randomized, open-label comparison of a long-acting basal insulin analog glargine plus glulisine with premixed insulin in insulin na\u00efve patients with Type 2 diabetes \u2013 A study from India"],"prefix":"10.1016","volume":"18","author":[{"given":"Arun","family":"Raghavan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Nanditha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-2162","authenticated-orcid":false,"given":"Krishnamoorthy","family":"Satheesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla","family":"Susairaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramachandran","family":"Vinitha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhruv Rajesh","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chamukuttan","family":"Snehalatha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8313-0502","authenticated-orcid":false,"given":"Ambady","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pcd.2024.01.006_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4158\/CS-2017-0153","article-title":"Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary","volume":"24","author":"Garber","year":"2018","journal-title":"Endocr. Pr."},{"key":"10.1016\/j.pcd.2024.01.006_bib2","unstructured":"International Diabetes Federation (IDF). Guideline for management of postmeal glucose. 2007 [online]. Available from URL: \u3008http:\/\/www.idf.org\/webdata\/docs\/Guideline_\u3009 PMG_final.pdf Accessed on 14th June 2022."},{"issue":"15","key":"10.1016\/j.pcd.2024.01.006_bib3","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9677","key":"10.1016\/j.pcd.2024.01.006_bib4","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pcd.2024.01.006_bib5","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"10.1016\/j.pcd.2024.01.006_bib6","doi-asserted-by":"crossref","first-page":"S212","DOI":"10.2337\/dcS13-2007","article-title":"Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?","volume":"36","author":"Mosenzon","year":"2013","journal-title":"Diabetes Care"},{"issue":"7 Suppl","key":"10.1016\/j.pcd.2024.01.006_bib7","first-page":"49","article-title":"Consensus evidence-based guidelines for insulin initiation, optimization and continuation in type 2 diabetes mellitus","volume":"62","author":"Shah","year":"2014","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.pcd.2024.01.006_bib8","doi-asserted-by":"crossref","unstructured":"Professional Practice Committee: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018; 41(Suppl 1):S3. doi:10.2337\/dc18-Sppc01.","DOI":"10.2337\/dc18-Sppc01"},{"key":"10.1016\/j.pcd.2024.01.006_bib9","first-page":"227","article-title":"Indian national consensus group: national guidelines on initiation and intensification of insulin therapy with premixed insulin analogs","volume":"2013","author":"Das","year":"2013","journal-title":"Med. Update"},{"issue":"1","key":"10.1016\/j.pcd.2024.01.006_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/00000441-200607000-00005","article-title":"Basal-prandial insulin therapy: scientific concept review and application","volume":"332","author":"Leahy","year":"2006","journal-title":"Am. J. Med. Sci."},{"issue":"12","key":"10.1016\/j.pcd.2024.01.006_bib11","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2337\/diabetes.49.12.2142","article-title":"Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro","volume":"49","author":"Lepore","year":"2000","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.pcd.2024.01.006_bib12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann. Intern Med."},{"issue":"10","key":"10.1016\/j.pcd.2024.01.006_bib13","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/diacare.27.10.2363","article-title":"Insulin glulisine provides improved glycemic control in patients with type 2 diabetes","volume":"27","author":"Dailey","year":"2004","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pcd.2024.01.006_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4158\/EP.11.1.11","article-title":"Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine","volume":"11","author":"Garg","year":"2005","journal-title":"Endocr. Pr."},{"issue":"3","key":"10.1016\/j.pcd.2024.01.006_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study","volume":"49","author":"Yki-J\u00e4rvinen","year":"2006","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pcd.2024.01.006_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003088-200847010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of insulin glulisine","volume":"47","author":"Becker","year":"2008","journal-title":"Clin. Pharm."},{"issue":"4","key":"10.1016\/j.pcd.2024.01.006_bib17","first-page":"154","article-title":"The new 'designer' insulins","volume":"18","author":"Lando","year":"2000","journal-title":"Clin. Diabetes"},{"issue":"4","key":"10.1016\/j.pcd.2024.01.006_bib18","first-page":"E1","article-title":"Insulin therapy for type 2 diabetes: making it work","volume":"59","author":"Dushay","year":"2010","journal-title":"J. Fam. Pr."},{"issue":"3","key":"10.1016\/j.pcd.2024.01.006_bib19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.diabet.2014.11.002","volume":"41","author":"Malek","year":"2015","journal-title":"Diabetes Metab."},{"issue":"4","key":"10.1016\/j.pcd.2024.01.006_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S2213-8587(15)00041-8","volume":"3","author":"Jia","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"5","key":"10.1016\/j.pcd.2024.01.006_bib21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/dom.12225","article-title":"Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections","volume":"16","author":"Riddle","year":"2014","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.pcd.2024.01.006_bib22","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/j.1464-5491.2012.03722.x","article-title":"A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study","volume":"29","author":"Bowering","year":"2012","journal-title":"Diabet. Med."},{"issue":"2","key":"10.1016\/j.pcd.2024.01.006_bib23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1463-1326.2009.01165.x","article-title":"Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study","volume":"12","author":"Fritsche","year":"2010","journal-title":"Diabetes Obes. Metab."},{"issue":"5","key":"10.1016\/j.pcd.2024.01.006_bib24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.clinthera.2010.05.001","volume":"32","author":"Miser","year":"2010","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.pcd.2024.01.006_bib25","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jdiacomp.2015.04.003","article-title":"Insulin glargine compared with premixed insulin for management of insulin-na\u00efve type 2 diabetes patients uncontrolled on oral antidiabetic drugs: the open-label, randomized GALAPAGOS study","volume":"29","author":"Aschner","year":"2015","journal-title":"J. Diabetes Complicat."},{"issue":"3","key":"10.1016\/j.pcd.2024.01.006_bib26","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/1753-0407.12312","article-title":"Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial","volume":"8","author":"Jin","year":"2016","journal-title":"J. Diabetes"},{"issue":"12","key":"10.1016\/j.pcd.2024.01.006_bib27","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/dme.13518","article-title":"Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data","volume":"34","author":"Anyanwagu","year":"2017","journal-title":"Diabet. Med."},{"issue":"5","key":"10.1016\/j.pcd.2024.01.006_bib28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s13300-021-01041-x","article-title":"A real-world, observational study of the initiation, use, and effectiveness of basal-bolus or premixed insulin in Japanese people with type 2 diabetes","volume":"12","author":"Miyoshi","year":"2021","journal-title":"Diabetes Ther."},{"issue":"1","key":"10.1016\/j.pcd.2024.01.006_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000679","article-title":"Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen","volume":"7","author":"Seufert","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"3","key":"10.1016\/j.pcd.2024.01.006_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/1753-0407.12312","article-title":"Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: a 24-week randomized non-inferiority trial","volume":"8","author":"Jin","year":"2016","journal-title":"J. Diabetes"},{"issue":"12","key":"10.1016\/j.pcd.2024.01.006_bib31","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1463-1326.2008.00967.x","article-title":"Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs","volume":"10","author":"Lankisch","year":"2008","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.pcd.2024.01.006_bib32","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.2337\/dc11-0900","article-title":"Optimizing insulin glargine plus one injection of insulin glulisine in type 2 diabetes in the ELEONOR study: similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction","volume":"34","author":"Nicolucci","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.pcd.2024.01.006_bib33","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1463-1326.2011.01459.x","article-title":"Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study","volume":"13","author":"Owens","year":"2011","journal-title":"Diabetes Obes. Metab."},{"issue":"3","key":"10.1016\/j.pcd.2024.01.006_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12020-015-0718-3","article-title":"Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"51","author":"Giugliano","year":"2016","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.pcd.2024.01.006_bib35","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00592-014-0698-4","article-title":"Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus","volume":"52","author":"Rys","year":"2015","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.pcd.2024.01.006_bib36","article-title":"Prevalence of complications of diabetes in people with type 2 diabetes: data from asia, africa, europe and latin america from the a A1chieve study","volume":"Vol. 60","author":"Zilov","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.pcd.2024.01.006_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820937217","article-title":"Suboptimal glycemic control among subjects with diabetes mellitus in India: a subset analysis of cross-sectional wave-7 (2016) data from the international diabetes management practices study (IDMPS)","volume":"11","author":"Ramachandran","year":"2020","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.pcd.2024.01.006_bib38","first-page":"243","article-title":"Factors associated with switching from oral hypoglycaemic agents to insulin therapy","volume":"60","author":"Spoelstra","year":"2002","journal-title":"Neth. J. Med."},{"issue":"7","key":"10.1016\/j.pcd.2024.01.006_bib39","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5694\/j.1326-5377.2006.tb00264.x","article-title":"Glycaemic levels triggering intensification of therapy in type 2 diabetes in the community: the fremantle diabetes study","volume":"184","author":"Davis","year":"2006","journal-title":"Med. J. Aust."},{"issue":"3","key":"10.1016\/j.pcd.2024.01.006_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.diabet.2009.11.006","article-title":"Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes","volume":"36","author":"Ringborg","year":"2010","journal-title":"Diabetes Metab."},{"issue":"1 Pt 2","key":"10.1016\/j.pcd.2024.01.006_bib41","doi-asserted-by":"crossref","first-page":"136","DOI":"10.7326\/0003-4819-124-1_Part_2-199601011-00011","article-title":"United Kingdom prospective diabetes study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus","volume":"124","author":"Turner","year":"1996","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.pcd.2024.01.006_bib42","doi-asserted-by":"crossref","unstructured":"U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249\u20131258. Erratum in: Diabetes 1996;45(11):1655. PMID: 7589820.","DOI":"10.2337\/diabetes.44.11.1249"},{"issue":"4","key":"10.1016\/j.pcd.2024.01.006_bib43","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N. Engl. J. Med."}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991824000068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991824000068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T10:30:03Z","timestamp":1729161003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991824000068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1751991824000068"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2024.01.006","relation":{},"ISSN":["1751-9918"],"issn-type":[{"type":"print","value":"1751-9918"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective, multicentre, randomized, open-label comparison of a long-acting basal insulin analog glargine plus glulisine with premixed insulin in insulin na\u00efve patients with Type 2 diabetes \u2013 A study from India","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2024.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}